PASCAL repair offers lasting TR reduction, better survival, and improved quality of life in severe tricuspid regurgitation.

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...

Millions of obese Americans could have weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new ...

Delhi continued to choke with ‘severe plus’ air quality for the second consecutive day. The smog engulfed the city.

Heart disease is a general term that describes problems with the heart. Congenital heart disease is a type of heart disease ...

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for ...

Per an HFSA news release, in the United States, it is estimated that heart failure prevalence may increase to 11.4 million by 2050.

A large population study of men over 45 indicates insulin resistance may be an important risk factor for the development of ...

Weight-Loss Drug Reduces Risk of Early Death for Patients With Heart Failure, Trial Finds Nov. 20 ... adulthood may cause an excess increase of 4 mmHg in systolic blood pressure, a new study ...

Food science students at UC Davis gain hands-on experience in the Food Product Development class. They come up with a new food concept ... Patients who have had a heart attack, heart surgery or heart ...